Marcadores séricos como predictores de mala evolución durante el segundo trimestre de embarazo (Mid-trimester maternal serum markers as a predictor of adverse pregnancy outcome)

Mid-trimester maternal serum AFP and hCG have been associated with adverse pregnancy outcomes in
the absence of aneuploidy or neural tube defects.
Mid-trimester maternal serum AFP levels > 2.5 MoM are thought to reflect a defect in placentation and
are associated with an increased risk of complications in later pregnancy including: late fetal loss, gestational
hypertension, preeclampsia, IUGR, preterm delivery and IUFD.
Mid-trimester maternal serum hCG > 2.5 MoM is associated with an increased risk of complications in
later pregnancy including: late fetal loss, gestational hypertension, preeclampsia, IUGR, preterm delivery
and IUFD.
Combined mid-trimester elevation in maternal serum AFP and hCG levels suggest a more complex type
of placental pathology. They are more strongly associated with complications in later pregnancy including:
late fetal loss, gestational hypertension, preeclampsia, IUGR, preterm delivery and IUFD.
Mid-trimester maternal serum AFP and/or hCG levels alone cannot detect all pregnant women with
increased risk of developing pregnancy complications. Multiparameter testing of placental function in
mid-trimester (maternal serum AFP and hCG screening, uterine artery Doppler and placental morphology)
may allow us to identify women with increased risk of developing severe placental insufficiency and
pregnancy complications.